{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T10:15:36Z","timestamp":1783419336313,"version":"3.54.6"},"reference-count":31,"publisher":"MJS Publishing, Medical Journals Sweden AB","license":[{"start":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T00:00:00Z","timestamp":1783382400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["SJU"],"abstract":"<jats:p>Objective: Magnetic resonance imaging (MRI) improves prostate cancer detection, but some tumours may be undetectable. This study assessed prostate cancer detection in biopsy-na\u00efve men undergoing first-time prostate MRI.\nMaterial and methods: In this nationwide Danish cohort (2018\u20132022), men aged \u2265\u200940 years undergoing first-time prostate MRI were classified as MRI-positive if biopsied within 30 days, and MRI-negative if not. This served as a proxy for the radiology report findings. One-year cumulative incidence of prostate cancer diagnosis in the Danish Prostate Cancer Registry, repeated MRI, biopsy and mortality was estimated by MRI-status (positive\/negative) and prostate-specific antigen (PSA) level, using the Aalen\u2013Johansen estimator. Occurrence of high-grade cancer was also assessed.\nResults: Among 10,777 men, 40% were MRI-positive and 60% MRI-negative. The cumulative incidence of prostate cancer was higher in the MRI-positive than the MRI-negative men during 1-year follow-up (63% vs. 5% at PSA levels 2\u20133.9\u00a0\u00b5g\/L), increasing with higher PSA levels (91% vs. 38% at PSA levels \u2265\u200920\u00a0\u00b5g\/L). At 1 year, repeated MRI occurred in 21% of MRI-positive men and 9% of MRI-negative men; the subsequent 1-year biopsy incidence was 15% among MRI-negative men. Mortality was comparable between MRI-positive and MRI-negative men (1% vs. 1%). The risk of high-grade prostate cancer at the time of diagnosis was 80% in MRI-positive and 74% in the MRI-negative men.\nConclusions: Among biopsy-na\u00efve men undergoing first-time prostate MRI, MRI-positive status strongly predicts prostate cancer, even in men with low PSA. In MRI-negative men with PSA &lt; 4.0\u00a0\u00b5g\/L, prostate cancer risk remains low within the 2-year follow-up.<\/jats:p>","DOI":"10.2340\/sju.v61.46161","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:37:44Z","timestamp":1783417064000},"page":"178-184","source":"Crossref","is-referenced-by-count":0,"title":["Detection of prostate cancer by magnetic resonance imaging before biopsy \u2013 real-world evidence from a nationwide cohort study"],"prefix":"10.2340","volume":"61","author":[{"given":"Amalie H","family":"Simoni","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne","family":"Ording","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jakob N.","family":"Hedegaard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Borre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u00f8ren P.","family":"Johnsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Henrik","family":"M\u00f8ller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1183","published-online":{"date-parts":[[2026,7,7]]},"reference":[{"key":"162109","doi-asserted-by":"crossref","unstructured":"Bergengren O, Pekala KR, Matsoukas K, et al. 2022 update on prostate cancer epidemiology and risk factors \u2013 a systematic review. Eur Urol. 2023;84:191\u2013206.","DOI":"10.1016\/j.eururo.2023.04.021"},{"key":"162110","unstructured":"Borre M, Elversang J, Hansen S, et al. The Danish Prostate Cancer Database annual report 2024. Aarhus: the Danish Healthcare Quality Institute; 2025."},{"key":"162111","doi-asserted-by":"crossref","unstructured":"Jahnen M, Hausler T, Meissner VH, et al. Predicting clinically significant prostate cancer following suspicious mpMRI: analyses from a high-volume center. World J Urol. 2024;42(1):290.","DOI":"10.1007\/s00345-024-04991-6"},{"key":"162112","doi-asserted-by":"crossref","unstructured":"Nakai H, Takahashi H, LeGout JD, et al. Estimated diagnostic performance of prostate MRI performed with clinical suspicion of prostate cancer. Insights Imaging. 2024;15(1):271.","DOI":"10.1186\/s13244-024-01845-y"},{"key":"162113","doi-asserted-by":"crossref","unstructured":"Wimper Y, F\u00fctterer JJ, Bomers JGR. MR imaging in real time guiding of therapies in prostate cancer. Life. 2022. Feb 17;12(2):302","DOI":"10.3390\/life12020302"},{"key":"162114","doi-asserted-by":"crossref","unstructured":"Mottet N, van den Bergh RCN, Briers E, et al. EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer \u2013 2020 update. Part 1: Screening, diagnosis, and local treatment with curative intent. Eur Urol. 2021;79:243\u2013262.","DOI":"10.1016\/j.eururo.2020.09.042"},{"key":"162115","doi-asserted-by":"crossref","unstructured":"Wysock JS, Mendhiratta N, Zattoni F, et al. Predictive value of negative 3T multiparametric magnetic resonance imaging of the prostate on 12-core biopsy results. BJU Int. 2016;118(4):515\u2013520.","DOI":"10.1111\/bju.13427"},{"key":"162116","doi-asserted-by":"crossref","unstructured":"Goldberg H, Ahmad AE, Chandrasekar T, et al. Comparison of magnetic resonance imaging and transrectal ultrasound informed prostate biopsy for prostate cancer diagnosis in biopsy na\u00efve men: a systematic review and meta-analysis. J Urol. 2020 Jun;203(6):1085\u20131092.","DOI":"10.1097\/JU.0000000000000595"},{"key":"162117","doi-asserted-by":"crossref","unstructured":"Guo E, Xu L, Zhang D, et al. Diagnostic performance of MRI in detecting prostate cancer in patients with prostate-specific antigen levels of 4\u201310 ng\/mL: a systematic review and meta-analysis. Insights Imaging. 2024;15(1): 147.","DOI":"10.1186\/s13244-024-01699-4"},{"key":"162118","doi-asserted-by":"crossref","unstructured":"Wibmer AG, Lefkowitz RA, Lakhman Y, et al. MRI-detectability of clinically significant prostate cancer relates to oncologic outcomes after prostatectomy. Clin Genitourin Cancer. 2022;20(4):319\u2013325.","DOI":"10.1016\/j.clgc.2022.04.001"},{"key":"162119","doi-asserted-by":"crossref","unstructured":"Hugosson J, Godtman RA, Wallstrom J, et al. Results after four years of screening for prostate cancer with PSA and MRI. N Engl J Med. 2024;391(12):1083\u20131095.","DOI":"10.1056\/NEJMoa2406050"},{"key":"162120","doi-asserted-by":"crossref","unstructured":"Padhani AR, Godtman RA, Schoots IG. Key learning on the promise and limitations of MRI in prostate cancer screening. Eur Radiol. 2024 Sep;34(9): 6168\u20136174.","DOI":"10.1007\/s00330-024-10626-6"},{"key":"162121","doi-asserted-by":"crossref","unstructured":"Diez NG, de Pablos-Rodr\u00edguez P, S\u00e1nchez-Mateos Manzaneque D, et al. Can we rely on magnetic resonance imaging for prostate cancer detection and surgical planning? Comprehensive analysis of a large cohort of patients undergoing transperineal mapped biopsies. World J Urol. 2024;42(1):548.","DOI":"10.1007\/s00345-024-05233-5"},{"key":"162122","doi-asserted-by":"crossref","unstructured":"Nguyen-Nielsen M, H\u00f8yer S, Friis S, et al. The Danish prostate cancer database. Clin Epidemiol. 2016 Oct;25:8:649\u2013653.","DOI":"10.2147\/CLEP.S100256"},{"key":"162123","unstructured":"Statistics Denmark. StatBank Denmark [Population] [Internet]. 2023 [cited 2025 Sep 10]. Available from:"},{"key":"162124","doi-asserted-by":"crossref","unstructured":"Frank L. Epidemiology. When an entire country is a cohort. Science. 2000;287(5462):2398\u20132399.","DOI":"10.1126\/science.287.5462.2398"},{"key":"162125","doi-asserted-by":"crossref","unstructured":"Schmidt M, Pedersen L, Sorensen HT. The Danish Civil Registration System as a tool in epidemiology. Eur J Epidemiol. 2014;29(8):541\u2013549.","DOI":"10.1007\/s10654-014-9930-3"},{"key":"162126","doi-asserted-by":"crossref","unstructured":"Schmidt M, Schmidt SA, Sandegaard JL, et al. The Danish National Patient Registry: a review of content, data quality, and research potential. Clin Epidemiol. 2015;7:449\u2013490.","DOI":"10.2147\/CLEP.S91125"},{"key":"162127","unstructured":"Dansk Prostata Cancer Database (DaProCa) \u2013 RKKP [Internet]. [cited 2023 May 16]. Available from: https:\/\/www.rkkp.dk\/kvalitetsdatabaser\/databaser\/dansk-prostata-cancer-database\/"},{"key":"162128","doi-asserted-by":"crossref","unstructured":"Grann AF, Erichsen R, Nielsen AG, et al. Existing data sources for clinical epidemiology: The clinical laboratory information system (LABKA) research database at Aarhus University, Denmark. Clin Epidemiol. 2011;3:133\u2013138.","DOI":"10.2147\/CLEP.S17901"},{"key":"162129","doi-asserted-by":"crossref","unstructured":"Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40(5):373\u2013383.","DOI":"10.1016\/0021-9681(87)90171-8"},{"key":"162130","doi-asserted-by":"crossref","unstructured":"Arafa MA, Rabah DM, Khan F, et al. False-positive magnetic resonance imaging prostate cancer correlates and clinical implications. Urol Ann. 2023;15(1):54\u201359.","DOI":"10.4103\/ua.ua_22_22"},{"key":"162131","doi-asserted-by":"crossref","unstructured":"Cheng Y, Fan B, Fu Y, et al. Prediction of false-positive PI-RADS 5 lesions on prostate multiparametric MRI: development and internal validation of a clinical-radiological characteristics based nomogram. BMC Urol. 2024;24(1):76.","DOI":"10.1186\/s12894-024-01465-0"},{"key":"162132","doi-asserted-by":"crossref","unstructured":"Ventimiglia E, Gedeborg R, Westerberg M, et al. Nationwide population-based longitudinal data on magnetic resonance imaging of the prostate and subsequent prostate biopsy results. Scand J Urol. 2026;61:64\u201371.","DOI":"10.2340\/sju.v61.45540"},{"key":"162133","doi-asserted-by":"crossref","unstructured":"Carter HB. Prostate cancers in men with low PSA levels \u2013 must we find them? N Engl J Med. 2004;350(22):2292\u20132294.","DOI":"10.1056\/NEJMe048003"},{"key":"162134","unstructured":"Bocia\u0144ski J, Sklinda K, Walecki J, et al. A case of high-grade prostate cancer with low PSA levels. Urol Case Rep. 2025 Aug 16;62:103161."},{"key":"162135","doi-asserted-by":"crossref","unstructured":"Obiora D, Orikogbo O, Davies BJ, et al. Controversies in prostate cancer screening. Urol Oncol. 2025 Jan;43(1):49\u201353.","DOI":"10.1016\/j.urolonc.2024.06.022"},{"key":"162136","doi-asserted-by":"crossref","unstructured":"Oh CU, Kang H. The effectiveness and harms of PSA-based prostate cancer screening: a systematic review. Healthcare. 2025. Jun 9;13(12):1381","DOI":"10.3390\/healthcare13121381"},{"key":"162137","doi-asserted-by":"crossref","unstructured":"Mahase E. Is the UK really ready to roll out prostate cancer screening? BMJ. 2023 May 17;381:p1062.","DOI":"10.1136\/bmj.p1062"},{"key":"162138","doi-asserted-by":"crossref","unstructured":"Vickers A, O\u2019Brien F, Montorsi F, et al. Current policies on early detection of prostate cancer create overdiagnosis and inequity with minimal benefit. BMJ. 2023 May17;381:e071082.","DOI":"10.1136\/bmj-2022-071082"},{"key":"162139","doi-asserted-by":"crossref","unstructured":"Fazekas T, Shim SR, Basile G, et al. Magnetic resonance imaging in prostate cancer screening. JAMA Oncol. 2024;10(6):745.","DOI":"10.1001\/jamaoncol.2024.0734"}],"container-title":["Scandinavian Journal of Urology"],"original-title":[],"link":[{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/46161\/54703","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/download\/46161\/54703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T09:38:44Z","timestamp":1783417124000},"score":1,"resource":{"primary":{"URL":"https:\/\/medicaljournalssweden.se\/SJU\/article\/view\/46161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,7]]},"references-count":31,"URL":"https:\/\/doi.org\/10.2340\/sju.v61.46161","relation":{},"ISSN":["2168-1813"],"issn-type":[{"value":"2168-1813","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,7]]}}}